NEW ORLEANS – An Arkansas woman alleges a prescription drug caused severe bleeding.
Dorothy May filed a complaint on April 7 in the U.S. District Court for the Eastern District of Louisiana against Jansen Research & Development LLC, Jansen Ortho LLL, Jansen Pharmaceuticals Inc., Johnson & Johnson Co., Bayer Pharma AG, Bayer Corp., Bayer Healthcare Pharmaceuticals Inc., Bayer Healthcare AG and Bayer AG, et al., citing manufacturing defect, design defect, failure to warn and other counts.
According to the complaint, the plaintiff alleges that, between Feb. 11, 2013 and Aug. 5, 2014, she ingested Xarelto, and suffered severe adverse bleeding on April 18, 2013; June 20, 2013; Sept. 30, 2013; and June 27, 2014. As a direct result of using Xarelto, she alleges she has suffered serious and dangerous side effects, life-threatening bleeding, as well as other severe and personal injuries which are permanent in nature, physical pain and mental anguish, loss of enjoyment of life, and medical expenses.
The plaintiff holds the defendants responsible because the defendants allegedly designed, researched, manufactured, tested, advertised, promoted, marketed distributed and sold Xarelto. They allegedly also failed to properly investigate, research, study and define, fully and adequately, the safety profile of Xarelto; failed to adequately test Xarelto; failed to provide adequate warnings; failed to disclose the need for dose adjustments; failed to provide adequate instructions; and failed to warn the medical professionals that there is no effective agent to reverse the effects of Xarelto.
The plaintiff requests a trial by jury and seeks compensation for economic and non-economic damages, punitive and/or exemplary damages, prejudgment and post-judgment interest, reasonable attorneys' fees and costs and for such other and further relief as the court may deem just and proper. She is represented by Kristian Rasmussen and Mitchell Theodore of Cory Watson PC in Birmingham, Alabama.
U.S. District Court for the Eastern District of Louisiana Case number 2:16-cv-02909